Nevanimibe

Nevanimibe is an orally active small molecule that acts as a selective inhibitor of acyl-coenzyme A:cholesterol O-acyltransferase 1 (ACAT1), with much lower activity against ACAT2[1][5]. By inhibiting ACAT1, nevanimibe blocks cholesterol esterification in the adrenal cortex and reduces adrenal steroid production. This mechanism was investigated for the treatment of diseases characterized by excess adrenal steroidogenesis such as endogenous Cushing's syndrome and classic congenital adrenal hyperplasia (CAH)[4][5]. Nevanimibe was originally developed by the University of Michigan and later advanced by Millendo Therapeutics. It received orphan drug designation for Cushing syndrome, congenital adrenal hyperplasia, and adrenocortical carcinoma[4]. Clinical development reached Phase 2 trials but was discontinued due to unfavorable data[4].

Other names

nevanimibe hydrochloridenevanimiba